Medicaid Drug Rebate Program: Inadequate Oversight Raises Concerns about Rebates Paid to States

United States Government Publishing Office publisher pbl distributor dst United States Government Accountability Office author aut Government Organization text government publication eng GAOREPORTS Legislative Agency Publications gao legislative 2010-08-12 U.S. Government Printing Office 2005-02-04 monographic deposited born digital 37 p. GA 1.13:GAO-05-102 https://www.govinfo.gov/app/details/GAOREPORTS-GAO-05-102 P0b002ee1803760da f:d05102 DGPO 2010-08-12 2011-03-28 GAOREPORTS-GAO-05-102 machine generated eng fdlp REPORT GAOREPORTS-GAO-05-102 GAO-05-102 Drugs Health care cost control Health insurance Pharmaceutical industry Prices and pricing Data integrity Manufacturing industry Rebates Medicaid Medicaid Drug Rebate Program Other Written Product A16936 Medicaid Drug Rebate Program: Inadequate Oversight Raises Concerns about Rebates Paid to States To help control Medicaid spending on drugs, states receive rebates from pharmaceutical manufacturers through the Medicaid drug rebate program. Rebates are based on two prices--best price and average manufacturer price (AMP)--reported by manufacturers. Both reflect manufacturers' prices to various entities, accounting for certain financial concessions like discounts. Concerns have been raised about rising Medicaid drug spending. GAO studied (1) federal oversight of manufacturer-reported best prices and AMPs and the methods used to determine them, (2) how manufacturers' determinations of those prices could have affected rebates, and (3) how the rebate program reflects financial concessions in the private market. https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-05-102/html/GAOREPORTS-GAO-05-102.htm https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-05-102/pdf/GAOREPORTS-GAO-05-102.pdf GAO-05-102 https://www.govinfo.gov/app/details/GAOREPORTS-GAO-05-102 Other Written Product GAO-05-102; Medicaid Drug Rebate Program: Inadequate Oversight Raises Concerns about Rebates Paid to States; Drugs Health care cost control Health insurance Pharmaceutical industry Prices and pricing Data integrity Manufacturing industry Rebates Medicaid Medicaid Drug Rebate Program United States Statutes at Large Volume 104 Page 1388 104 Stat. 1388